Beaufort Securities Reiterates “Speculative Buy” Rating for ValiRx (VAL)

ValiRx (LON:VAL)‘s stock had its “speculative buy” rating reaffirmed by equities researchers at Beaufort Securities in a research report issued on Friday.

Shares of ValiRx (LON:VAL) opened at GBX 4.88 ($0.07) on Friday. The stock has a market cap of $12.78 and a price-to-earnings ratio of -81.25. ValiRx has a 52 week low of GBX 0.90 ($0.01) and a 52 week high of GBX 7.75 ($0.11).

ILLEGAL ACTIVITY NOTICE: “Beaufort Securities Reiterates “Speculative Buy” Rating for ValiRx (VAL)” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at

ValiRx Company Profile

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.

Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with's FREE daily email newsletter.

Leave a Reply